Abdala Priscilla Maria Fernandes, Iyomasa Mamie Mizusaki, Sato Sandra, Bentley Maria Vitória Lopes Badra, Pitol Dimitrius Leonardo, Regalo Simone Cecílio Hallak, Siéssere Selma, Issa João Paulo Mardegan
Department of Morphology, Oral Medicine and Physiology, Faculty of Dentistry, University of São Paulo, Av. Café S/N, Bairro: Monte Alegre, Ribeirão Preto, São Paulo 14040-904, Brazil.
Anat Sci Int. 2010 Dec;85(4):181-8. doi: 10.1007/s12565-010-0075-5. Epub 2010 Mar 4.
The objective of this study was to evaluate bone formation after application of different doses of recombinant human bone morphogenetic protein-2 (rhBMP-2) combined with monoolein or poloxamer gels, in critical bone defects of rats. Forty-five Wistar rats were divided into nine treatment groups with five animals each: I: application of 1 µg rhBMP-2 + monoolein; II: 3 µg rhBMP-2 + monoolein; III: 7 µg rhBMP-2 + monoolein; IV: 1 µg rhBMP-2 + poloxamer; V: 3 µg rhBMP-2 + poloxamer; VI: 7 µg rhBMP-2 + poloxamer; VII: monoolein only; VIII: poloxamer only; and IX: critical bone defect only. A critical-sized defect of 6 mm diameter was produced in the left parietal bone and it was filled with gels of the above mentioned treatments. After 2 weeks, the calvarial bones were removed for histological processing. Bone formation in the groups that received poloxamer gel and rhBMP-2 was not significantly different from the control group (IX). Groups receiving monoolein and rhBMP-2 (1 and 3 µg) and those that received only the carriers (VII and VIII) had less bone formation in relation to the control. The association of rhBMP-2 to both poloxamer and monoolein did not exhibit any significant differentiation in bone formation in comparison with the control group.
本研究的目的是评估在大鼠严重骨缺损中应用不同剂量重组人骨形态发生蛋白-2（rhBMP-2）联合单油酸甘油酯或泊洛沙姆凝胶后的骨形成情况。45只Wistar大鼠被分为9个治疗组，每组5只动物：I组：应用1μg rhBMP-2 + 单油酸甘油酯；II组：3μg rhBMP-2 + 单油酸甘油酯；III组：7μg rhBMP-2 + 单油酸甘油酯；IV组：1μg rhBMP-2 + 泊洛沙姆；V组：3μg rhBMP-2 + 泊洛沙姆；VI组：7μg rhBMP-2 + 泊洛沙姆；VII组：仅用单油酸甘油酯；VIII组：仅用泊洛沙姆；IX组：仅为严重骨缺损。在左顶骨制造一个直径6mm的临界尺寸缺损，并用上述治疗的凝胶填充。2周后，取出颅骨进行组织学处理。接受泊洛沙姆凝胶和rhBMP-2的组中的骨形成与对照组（IX组）无显著差异。接受单油酸甘油酯和rhBMP-2（1μg和3μg）的组以及仅接受载体的组（VII组和VIII组）相对于对照组骨形成较少。与对照组相比，rhBMP-2与泊洛沙姆和单油酸甘油酯的联合在骨形成方面未表现出任何显著差异。
